Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$3.81
-11.5%
$4.85
$3.16
▼
$11.89
$55.48M-0.88355,564 shs135,622 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$0.31
-1.8%
$0.33
$0.26
▼
$1.58
$58.03M1.653.14 million shs1.29 million shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.40
$1.78
$1.22
▼
$3.90
$68.66M0.71134,287 shs8,966 shs
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$3.70
-0.1%
$5.00
$3.25
▼
$23.50
$17.75M1.71258,157 shs9,029 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
0.00%+0.94%-1.38%-17.47%+23.21%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
0.00%+5.97%-13.99%-2.97%-71.77%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-4.45%-1.76%+5.68%-10.00%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
0.00%-0.67%-5.13%-28.71%-75.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$3.81
-11.5%
$4.85
$3.16
▼
$11.89
$55.48M-0.88355,564 shs135,622 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$0.31
-1.8%
$0.33
$0.26
▼
$1.58
$58.03M1.653.14 million shs1.29 million shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.40
$1.78
$1.22
▼
$3.90
$68.66M0.71134,287 shs8,966 shs
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$3.70
-0.1%
$5.00
$3.25
▼
$23.50
$17.75M1.71258,157 shs9,029 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
0.00%+0.94%-1.38%-17.47%+23.21%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
0.00%+5.97%-13.99%-2.97%-71.77%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-4.45%-1.76%+5.68%-10.00%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
0.00%-0.67%-5.13%-28.71%-75.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
2.50
Moderate Buy$27.00609.41% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
1.75
Reduce$2.00555.74% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.71
Moderate Buy$7.75455.56% Upside
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
2.60
Moderate Buy$17.33369.10% Upside

Current Analyst Ratings Breakdown

Latest QNRX, MNOV, HRTX, and CING Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
11/3/2026
Cingulate Inc. stock logo
CING
Cingulate
DowngradeSell (D-) ➝ Sell (E+)
10/20/2026
Cingulate Inc. stock logo
CING
Cingulate
UpgradeSell (E+) ➝ Sell (D-)
10/19/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$18.00
10/16/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Reiterated RatingSell (E+)
10/15/2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Reiterated RatingSell (E+)
10/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$14.00
10/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$14.00
10/2/2026
Cingulate Inc. stock logo
CING
Cingulate
DowngradeSell (D-) ➝ Sell (E+)
9/29/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Reiterated RatingBuy
9/23/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$20.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$0.31 per shareN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$148.22M0.39N/AN/A$0.07 per share4.36
MediciNova, Inc. stock logo
MNOV
MediciNova
$920.48K74.60N/AN/A$0.85 per share1.64
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/A$15.64 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$22.45M-$2.77N/AN/AN/AN/A-195.26%-110.83%N/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$20.19M-$0.12N/AN/AN/A-14.55%-277.36%-8.76%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.21N/AN/AN/A-1,126.60%-26.47%-24.24%N/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$15.81M-$19.44N/AN/AN/AN/A-227.75%-149.97%N/A

Latest QNRX, MNOV, HRTX, and CING Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Cingulate Inc. stock logo
CING
Cingulate
-$0.4325-$0.53-$0.0975-$0.53$0.54 millionN/A
11/12/2026Q3 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.0625-$0.06+$0.0025-$0.06$0.05 million$0.14 million
11/9/2026Q3 2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.03-$0.03N/A-$0.03$37.50 million$35.25 million
11/5/2026Q3 2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$1.5157-$0.97+$0.5457-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
N/A
3.50
3.50
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
32.59
2.33
1.31
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
8.75
8.75
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/A
7.20
7.20

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
8.63%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.30%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
6.10%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.00%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
7.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
1414.54 million13.77 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
128190.27 million178.67 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
649.22 million42.33 millionOptionable
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
44.80 million4.44 millionNot Optionable

Recent News About These Companies

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cingulate stock logo

Cingulate NASDAQ:CING

$3.80 -0.50 (-11.51%)
As of 12:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$0.30 -0.01 (-1.77%)
As of 12:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.40 0.00 (0.00%)
As of 12:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Quoin Pharmaceuticals stock logo

Quoin Pharmaceuticals NASDAQ:QNRX

$3.70 -0.01 (-0.14%)
As of 12:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.